Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL29273171 | 0.93 | CA1 (0.43) | CA4FAHD1CA1MEN1LDHA | |
| Bicarbonate SCHEMBL226679 | 0.88 | CA4 (0.40) | CA4FAHD1CA1MEN1LDHA | |
| Bicarbonate SCHEMBL3326642 | 0.87 | CA4 (0.46) | CA4FAHD1CA1MEN1LDHA | |
| Bicarbonate SCHEMBL5912779 | 0.87 | CA1 (0.46) | CA4FAHD1CA1CA2CA9 | |
| Sulfurous Acid SCHEMBL11718648 | 0.87 | — | — | |
| Bicarbonate SCHEMBL10755209 | 0.83 | — | — | |
| Oxalic Acid SCHEMBL28071621 | 0.83 | OR51E2 (0.33) | CA4FAHD1CA1LDHACA2 | |
| Bicarbonate SCHEMBL28179570 | 0.82 | — | — | |
| Bicarbonate SCHEMBL6566883 | 0.82 | CA4 (0.35) | CA4FAHD1CA1MEN1LDHA | |
| Bicarbonate SCHEMBL1332636 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3394066-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| EP-1699291-B1 | PLANT GROWTH REGULATION | BAYER CROPSCIENCE AG (DE) | 2009-09-02 | — | — | EP | disclosed |
| US-7569516-B2 | Plant growth regulation | BAYER CROPSCIENCE AG (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20070149406-A1 | Plant growth regulation | BAYER CROPSCIENCE GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| CN-1938323-A | Silinane compounds as cysteine protease inhibitors | SCHERING AG (DE) | 2007-03-28 | — | — | CN | disclosed |
| EP-1699291-A1 | PLANT GROWTH REGULATION | Bayer CropScience GmbH (DE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005063020-A1 | PLANT GROWTH REGULATION | BAYER CROPSCIENCE GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
| EP-1550370-A1 | Plant growth regulation | Bayer CropScience GmbH (DE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
| EP-1028955-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024420-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1999-05-20 | — | — | WO | disclosed |
| US-5225422-A | Antiallergens, antiinflammatory agents | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0516069-A1 | Leukotriene B4 antagonist | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-12-02 | — | — | EP | disclosed |
| US-5112855-A | Nootropic Agents | CIBA-GEIGY CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| US-4957928-A | NOOTROPIC AGENTS, COGNITION ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | CA4 4756/4885FAHD1 868/4885CA1 4810/4885 |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | CA4 4636/4885FAHD1 1222/4885CA1 4860/4885 |
| US-20070149406-A1 | Plant growth regulation | GHDC, GTF2I, GHITM | CA4 2784/4885FAHD1 4578/4885CA1 4564/4885 |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | CA4 4636/4885FAHD1 1222/4885CA1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.